|
|
Vaccine Detail
|
HyperAcute-Melanoma Vaccine |
| Vaccine Information |
- Vaccine Name: HyperAcute-Melanoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: alpha(1,3)galactosyl-epitopes (alpha-gal) (NCT00300612)
- Immunization Route: Intradermal injection (i.d.)
- Description: The expression of the murine alpha(1,3)galactosyltransferase [alpha(1,3)GT] gene results in the cell surface expression of alpha(1,3)galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids.Patients with advanced stage melanoma can be vaccinated with this trivalent vaccine composed of irradiated allogeneic melanoma cell lines (HAM-1, HAM-2 and HAM-3). These cell lines have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha(1,3)GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink. (NCT00300612)
|
| Host Response |
|
|
| References |
NCT00300612: Vaccine Treatment for Advanced Malignant Melanoma [https://clinicaltrials.gov/study/NCT00300612]
|
|
